Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.63 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | RXRG | P48443 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561119 | 0.93 | POLA1 (0.71) | POLA1KARS1POLBAPEX1PDE4D | |
| Trifluoroacetic Acid SCHEMBL28618126 | 0.90 | SOD1 (0.60) | POLA1POLBAPEX1NR1H2NR1H3 | |
| Trifluoroacetic Acid SCHEMBL29493569 | 0.90 | SOD1 (0.60) | POLA1POLBAPEX1NR1H2NR1H3 | |
| SCHEMBL21552218 | 0.84 | NR1H2 (0.64) | POLA1POLBAPEX1NR1H2NR1H3 | |
| SCHEMBL24591989 | 0.84 | NR1H2 (0.62) | POLA1KARS1POLBAPEX1PDE4D | |
| SCHEMBL2986350 | 0.84 | LMNA (0.65) | POLA1KARS1PDE4DRXRACCNE1 | |
| SCHEMBL21569919 | 0.84 | NR1H2 (0.62) | POLA1KARS1POLBAPEX1PDE4D | |
| SCHEMBL21552174 | 0.82 | NR1H2 (0.77) | POLA1NR1H2NR1H3 | |
| SCHEMBL5061708 | 0.82 | POLA1 (0.71) | POLA1KARS1POLBAPEX1PDE4D | |
| SCHEMBL24591823 | 0.81 | SOD1 (0.69) | POLA1NR1H2NR1H3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3790899-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | POLA1 2693/4885KARS1 2490/4885POLB 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.